

# Yongrong Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6508278/publications.pdf>

Version: 2024-02-01

23  
papers

709  
citations

687363

13  
h-index

642732

23  
g-index

24  
all docs

24  
docs citations

24  
times ranked

831  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mouse Relapse Model of Clostridium difficile Infection. Infection and Immunity, 2011, 79, 2856-2864.	2.2	92
2	Mechanisms of Protection against Clostridium difficile Infection by the Monoclonal Antitoxin Antibodies Actoxumab and Bezlotoxumab. Infection and Immunity, 2015, 83, 822-831.	2.2	88
3	A Chimeric Toxin Vaccine Protects against Primary and Recurrent Clostridium difficile Infection. Infection and Immunity, 2012, 80, 2678-2688.	2.2	81
4	Systemic Dissemination of Clostridium difficile Toxins A and B Is Associated With Severe, Fatal Disease in Animal Models. Journal of Infectious Diseases, 2012, 205, 384-391.	4.0	76
5	A probiotic yeast-based immunotherapy against Clostridioides difficile infection. Science Translational Medicine, 2020, 12, .	12.4	61
6	Structure of the full-length Clostridium difficile toxin B. Nature Structural and Molecular Biology, 2019, 26, 712-719.	8.2	59
7	Critical Roles of Clostridium difficile Toxin B Enzymatic Activities in Pathogenesis. Infection and Immunity, 2015, 83, 502-513.	2.2	31
8	Mice with Inflammatory Bowel Disease are Susceptible to Clostridium difficile Infection With Severe Disease Outcomes. Inflammatory Bowel Diseases, 2018, 24, 573-582.	1.9	29
9	Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B. PLoS Biology, 2019, 17, e3000311.	5.6	24
10	A Segment of 97 Amino Acids within the Translocation Domain of Clostridium difficile Toxin B Is Essential for Toxicity. PLoS ONE, 2013, 8, e58634.	2.5	22
11	Immunotherapy using IL-2 and GM-CSF is a potential treatment for multidrug-resistant Mycobacterium tuberculosis. Science China Life Sciences, 2012, 55, 800-806.	4.9	20
12	Newly identified bacteriolytic enzymes that target a wide range of clinical isolates of Clostridium difficile. Biotechnology and Bioengineering, 2016, 113, 2568-2576.	3.3	20
13	Glucosyltransferase activity of Clostridium difficile Toxin B is essential for disease pathogenesis. Gut Microbes, 2015, 6, 221-224.	9.8	17
14	Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection. Pathogens and Disease, 2016, 74, ftw078.	2.0	16
15	Cysteine Protease-Mediated Autocleavage of Clostridium difficile Toxins Regulates Their Proinflammatory Activity. Cellular and Molecular Gastroenterology and Hepatology, 2018, 5, 611-625.	4.5	14
16	Masking autoprocessing of Clostridium difficile toxin A by the C-terminus combined repetitive oligo peptides. Biochemical and Biophysical Research Communications, 2015, 459, 259-263.	2.1	13
17	A Multiparticulate Delivery System for Potential Colonic Targeting Using Bovine Serum Albumin as a Model Protein. Pharmaceutical Research, 2017, 34, 2663-2674.	3.5	11
18	The role of purified Clostridium difficile glucosylating toxins in disease pathogenesis utilizing a murine cecum injection model. Anaerobe, 2017, 48, 249-256.	2.1	9

#	ARTICLE	IF	CITATIONS
19	The development of live biotherapeutics against <i>Clostridioides difficile</i> infection towards reconstituting gut microbiota. <i>Gut Microbes</i> , 2022, 14, 2052698.	9.8	9
20	Retargeting <i>Clostridium difficile</i> Toxin B to Neuronal Cells as a Potential Vehicle for Cytosolic Delivery of Therapeutic Biomolecules to Treat Botulism. <i>Journal of Toxicology</i> , 2012, 2012, 1-9.	3.0	7
21	Pathogenic effects of glucosyltransferase from <i>Clostridium difficile</i> toxins. <i>Pathogens and Disease</i> , 2016, 74, ftw024.	2.0	4
22	Spray layering of human immunoglobulin G: Optimization of formulation and process parameters. <i>International Journal of Pharmaceutics</i> , 2021, 610, 121238.	5.2	4
23	Establishment of a gnotobiotic pig model of <i>Clostridioides difficile</i> infection and disease. <i>Gut Pathogens</i> , 2022, 14, .	3.4	1